XML 59 R46.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables) | 12 Months Ended
--- | ---
Mar. 29, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | Selected information by reportable segment is presented below:
(In thousands) | 2025 |  | 2024 |  | 2023
Net sales |  |  |  |  |
Plasma | $ | 535,431 |  |  | $ | 569,535 |  |  | $ | 499,916 |
Blood Center | 261,124 |  |  | 283,231 |  |  | 287,034 |
Hospital | 564,269 |  |  | 456,289 |  |  | 381,710 |
Net sales by business unit | $ | 1,360,824 |  |  | $ | 1,309,055 |  |  | $ | 1,168,660 |
Significant segment expenses and operating performance |  |  |  |  |
Plasma |  |  |  |  |
Cost of goods sold | $ | 237,050 |  |  | $ | 264,042 |  |  | $ | 254,474 |
Selling, general and administrative | 98,418 |  |  | 109,729 |  |  | 106,006 |
Research and development | 15,453 |  |  | 13,797 |  |  | 14,690 |
Plasma operating income | $ | 184,510 |  |  | $ | 181,967 |  |  | $ | 124,746 |
Blood Center |  |  |  |  |
Cost of goods sold | $ | 142,512 |  |  | $ | 165,564 |  |  | $ | 144,364 |
Selling, general and administrative | 60,023 |  |  | 67,339 |  |  | 74,024 |
Research and development | 5,770 |  |  | 7,956 |  |  | 4,374 |
Blood Center operating income | $ | 52,819 |  |  | $ | 42,372 |  |  | $ | 64,272 |
Hospital |  |  |  |  |
Cost of goods sold | $ | 199,499 |  |  | $ | 167,172 |  |  | $ | 147,831 |
Selling, general and administrative | 241,760 |  |  | 209,680 |  |  | 181,368 |
Research and development | 34,035 |  |  | 27,239 |  |  | 23,096 |
Hospital operating income | $ | 88,975 |  |  | $ | 52,198 |  |  | $ | 29,415 |
Corporate and unallocated expenses |  |  |  |  |
Amortization of acquired assets | $ | (63,217) |  |  | $ | (35,378) |  |  | $ | (32,640) |
Acquisition, integration and divestiture related costs | (22,904) |  |  | (11,249) |  |  | 411 |
Restructuring and restructuring related costs | (21,158) |  |  | (23,588) |  |  | (11,549) |
Digital transformation costs | (20,273) |  |  | (15,667) |  |  | (4,536) |
Contingent Consideration | 23,022 |  |  | — |  |  | — |
Other(1) | 43 |  |  | (25,772) |  |  | (14,086) |
Operating income | 221,817 |  |  | 164,883 |  |  | 156,033 |
Interest and other expense, net | (9,746) |  |  | (13,018) |  |  | (14,630) |
Income before provision for income taxes | $ | 212,071 |  |  | $ | 151,865 |  |  | $ | 141,403 |
(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2® related charges and gain on divestiture.
Net revenues by business unit are as follows:
(In thousands) | 2025 |  | 2024 |  | 2023
| Plasma | $ | 535,431 |  |  | $ | 569,535 |  |  | $ | 499,916 |
| Apheresis | 213,134 |  |  | 211,173 |  |  | 207,618 |
| Whole Blood | 47,990 |  |  | 72,058 |  |  | 79,416 |
| Blood Center | 261,124 |  |  | 283,231 |  |  | 287,034 |
| Interventional Technologies | 255,019 |  |  | 174,285 |  |  | 126,717 |
| Blood Management Technologies | 309,250 |  |  | 282,004 |  |  | 254,993 |
| Hospital | $ | 564,269 |  |  | $ | 456,289 |  |  | $ | 381,710 |
Total net revenues | $ | 1,360,824 |  |  | $ | 1,309,055 |  |  | $ | 1,168,660 |
(In thousands) | 2025 |  | 2024 |  | 2023
Depreciation and amortization |  |  |  |  |
Plasma | $ | 48,264 |  |  | $ | 45,712 |  |  | $ | 41,612 |
Blood Center | 10,077 |  |  | 13,391 |  |  | 13,927 |
Hospital | 57,245 |  |  | 38,112 |  |  | 37,768 |
Total depreciation and amortization (excluding impairment charges) | $ | 115,586 |  |  | $ | 97,215 |  |  | $ | 93,307 |
(In thousands) | March 29, 2025 |  | March 30, 2024 |  |
Long-lived assets(1) |  |  |  |  |
Plasma | $ | 189,833 |  |  | $ | 211,121 |  |  |
Blood Center | 40,337 |  |  | 54,262 |  |  |
Hospital | 53,882 |  |  | 45,979 |  |  |
Total long-lived assets | $ | 284,052 |  |  | $ | 311,362 |  |  |
(1) Long-lived assets are comprised of property, plant and equipment.
Segment Information by Geographic Area | Selected information by operating regions is presented below:
(In thousands) | March 29, 2025 |  | March 30, 2024 |  |
Long-lived assets(1) |  |  |  |  |
United States | $ | 217,212 |  |  | $ | 246,473 |  |  |
Japan | 1,250 |  |  | 1,597 |  |  |
Europe | 20,024 |  |  | 15,310 |  |  |
Rest of Asia | 28,705 |  |  | 26,728 |  |  |
Other | 16,861 |  |  | 21,254 |  |  |
Total long-lived assets | $ | 284,052 |  |  | $ | 311,362 |  |  |
(1) Long-lived assets are comprised of property, plant and equipment.
(In thousands) | 2025 |  | 2024 |  | 2023
Net revenues |  |  |  |  |
United States | $ | 1,010,918 |  |  | $ | 970,007 |  |  | $ | 842,897 |
Japan | 62,408 |  |  | 58,087 |  |  | 61,295 |
Europe | 175,655 |  |  | 160,142 |  |  | 156,680 |
Rest of Asia | 92,305 |  |  | 107,536 |  |  | 104,135 |
Other | 19,538 |  |  | 13,283 |  |  | 3,653 |
Total net revenues | $ | 1,360,824 |  |  | $ | 1,309,055 |  |  | $ | 1,168,660 |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration